Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.67 |
| ▸ | ACHE | P22303 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7308829 | 0.88 | MAOB (0.53) | MAOBACHEKDM4EMAPTMAOA | |
| SCHEMBL7302123 | 0.85 | MAOB (0.77) | MAOBACHEMAOA | |
| SCHEMBL9136381 | 0.82 | MAOB (0.44) | MAOBKDM4EMAPT | |
| SCHEMBL7301156 | 0.81 | MAOB (0.70) | MAOBACHEKDM4EMAOA | |
| Atibeprone SCHEMBL2111018 | 0.81 | MAOB (1.00) | MAOBACHEMAOA | |
| SCHEMBL5618346 | 0.80 | MAOB (0.53) | MAOBACHEMAOA | |
| SCHEMBL7294868 | 0.78 | MAOB (0.64) | MAOBACHEKDM4E | |
| SCHEMBL7293827 | 0.77 | MAOB (0.65) | MAOBACHEKDM4EMAOA | |
| SCHEMBL7291407 | 0.76 | MAOB (0.64) | MAOBACHEKDM4EMAOA | |
| SCHEMBL7295471 | 0.76 | ACHE (0.56) | MAOBACHEMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| EP-0363796-B1 | HETEROCYCLICALLY SUBSTITUTED ALKOXYCOUMARINES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL AGENTS CONTAINING SAME | BASF Aktiengesellschaft (DE) | 1993-08-11 | — | — | EP | disclosed |
| US-5227392-A | Monoamine oxidase inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1993-07-13 | — | — | US | disclosed |
| US-5073563-A | Enzyme inhibitors, CNS | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-17 | — | — | US | disclosed |
| EP-0363796-A1 | Heterocyclically substituted alkoxycoumarines, method for their preparation and therapeutical agents containing same | BASF Aktiengesellschaft (DE) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885ACHE 639/4885KDM4E 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.